A phase 2, randomized, double blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients (SAV005-02)

Grants and Contracts Details

StatusFinished
Effective start/end date3/13/13 → 3/31/15

Funding

  • Savara Incorporated: $6,598.00